NASDAQ:ZGNX - Zogenix Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$41.44 -0.43 (-1.03 %)
(As of 12/16/2018 03:43 PM ET)
Previous Close$41.44
Today's Range$40.93 - $42.90
52-Week Range$33.42 - $62.75
Volume571,998 shs
Average Volume512,806 shs
Market Capitalization$1.74 billion
P/E Ratio-10.31
Dividend YieldN/A
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Current SymbolNASDAQ:ZGNX
Previous Symbol


Debt-to-Equity RatioN/A
Current Ratio9.89
Quick Ratio9.89


Trailing P/E Ratio-10.31
Forward P/E Ratio-10.79
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.82 million
Price / Sales177.11
Cash FlowN/A
Price / Cash FlowN/A
Book Value$8.80 per share
Price / Book4.71


EPS (Most Recent Fiscal Year)($4.02)
Net Income$-126,810,000.00
Net MarginsN/A
Return on Equity-38.56%
Return on Assets-28.83%


Outstanding Shares41,970,000
Market Cap$1.74 billion

Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) posted its quarterly earnings results on Thursday, November, 8th. The company reported ($1.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.88) by $0.20. During the same quarter in the previous year, the firm posted ($1.68) earnings per share. View Zogenix's Earnings History.

When is Zogenix's next earnings date?

Zogenix is scheduled to release their next quarterly earnings announcement on Tuesday, March 5th 2019. View Earnings Estimates for Zogenix.

What price target have analysts set for ZGNX?

9 Wall Street analysts have issued 12-month price objectives for Zogenix's shares. Their forecasts range from $60.00 to $116.00. On average, they anticipate Zogenix's share price to reach $73.00 in the next twelve months. This suggests a possible upside of 76.2% from the stock's current price. View Analyst Price Targets for Zogenix.

What is the consensus analysts' recommendation for Zogenix?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zogenix.

What are Wall Street analysts saying about Zogenix stock?

Here are some recent quotes from research analysts about Zogenix stock:
  • 1. Mizuho analysts commented, "We continue to see Fintepla as highly differentiated from competitor products with the potential for higher pricing and market share. The most important catalyst is a potential FDA approval in DS in 2019. Beyond DS, we see potential for for which data is anticipated in 1Q20." (12/6/2018)
  • 2. According to Zacks Investment Research, "Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, Sumavel™ DosePro™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA. " (11/17/2018)

Has Zogenix been receiving favorable news coverage?

Media headlines about ZGNX stock have been trending positive on Sunday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zogenix earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an effect on the stock's share price in the next few days.

Who are some of Zogenix's key competitors?

Who are Zogenix's key executives?

Zogenix's management team includes the folowing people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 59)
  • Mr. Roger L. Hawley B.S., Co-Founder & Director (Age 65)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 50)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 56)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 54)

Who are Zogenix's major shareholders?

Zogenix's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Scopia Capital Management LP (14.81%), Perceptive Advisors LLC (10.63%), BlackRock Inc. (10.06%), Bank of New York Mellon Corp (7.11%), Vanguard Group Inc. (4.93%) and Vanguard Group Inc (4.93%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Erle T Mast, Gail M Farfel, Life Sciences Maste Perceptive, Renee P Tannenbaum and Roger Hawley. View Institutional Ownership Trends for Zogenix.

Which institutional investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Perceptive Advisors LLC, Franklin Resources Inc., Artal Group S.A., Alliancebernstein L.P., Dimensional Fund Advisors LP, Eagle Asset Management Inc. and Credit Suisse AG. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner, Erle T Mast, Gail M Farfel and Roger Hawley. View Insider Buying and Selling for Zogenix.

Which institutional investors are buying Zogenix stock?

ZGNX stock was purchased by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Bank of New York Mellon Corp, BlackRock Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, Vanguard Group Inc, Vanguard Group Inc. and Loomis Sayles & Co. L P. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer, Life Sciences Maste Perceptive and Renee P Tannenbaum. View Insider Buying and Selling for Zogenix.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $41.44.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.74 billion and generates $9.82 million in revenue each year. The company earns $-126,810,000.00 in net income (profit) each year or ($4.02) on an earnings per share basis. Zogenix employs 68 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is

How can I contact Zogenix?

Zogenix's mailing address is 5858 Horton Street Suite 455, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]

MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  331 (Vote Outperform)
Underperform Votes:  224 (Vote Underperform)
Total Votes:  555
MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by Staff

Featured Article: How mutual funds make money

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel